Scilex Holding Quick Ratio (SCLX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
SCLX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0 a new company low.
Within Biotechnology & Pharmaceuticals industry 146 other companies have achieved higher Quick Ratio than Scilex Holding in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 3755 to 4519.
In a move to strengthen its position in the non-opioid pain management market, Scilex Holding Company recently announced a significant development. The company has entered into a commitment letter with Perigrove LLC and Graf Holdings for a $100 million 5-year term financing with royalty-based payments. This financing will allow Scilex to repay its existing senior secured loan and allocate additional funds for general corporate purposes. This announcement comes on the heels of Scilex s notice to lenders of short positions in restricted dividend shares, aimed at promoting transparency and integrity within the industry. By taking proactive steps to address potential issues, Scilex is demonstrating its commitment to upholding high standards in pain management.
Palo Alto-based Scilex Holding Company, a revenue-generating firm specializing in non-opioid pain management products, has recently finalized a definitive agreement with institutional investors for the purchase and sale of its common stock. The company plans to utilize the proceeds from the registered direct offering to advance its efforts in acquiring, developing, and commercializing innovative solutions for the treatment of acute and chronic pain. A Decrease in Quick Ratio Raises Concerns: In the midst of Scilex Holding Company s growth and expansion plans, a notable increase in current liabilities during the third quarter of 2023 resulted in a significant drop in the company s quick ratio. With the quick ratio falling to 0.01, the lowest level ever recorded in the company s history, concerns arise regarding its ability to meet short-term obligations and efficiently manage its financial position.
In a groundbreaking move, Scilex Holding Company, a leading provider of non-opioid pain management solutions, has closed a highly successful $10 million bought deal offering. The innovative revenue-generating company, focused on developing and commercializing products for acute and chronic pain treatment, announced the closing of this public offering along with the issuance of accompanying common warrants. This significant capital infusion will enable Scilex Holding Company to further its mission of revolutionizing pain management and expanding its market presence. Addressing Past Challenges: Despite an increase in Current Liabilities during the third quarter of 2023, Scilex Holding Company faced a dip in its Quick Ratio, which dropped to a new company low of 0.01. This figure placed the company far behind its industry peers, as 155 other companies reported higher Quick Ratios during the same period. Comparing the Quick Ratio to all other companies, Scilex Holding Company s ranking plummeted from 0.33 in the second quarter of 2023 to 3774. However, on a trailing twelve-month basis, Scilex Holding Company managed to maintain a Quick Ratio of 0.1, which exceeded its own average. It is worth noting that over the past year, a significant number of companies within the industry outperformed Scilex Holding Company in terms of Quick Ratio, resulting in a detrimental decline in its overall ranking from 3376 to 3900.
On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q2 2026 to $512.24 millions, cumulative Quick Ratio remained unchanged at 0.01 below the average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Biotechnology & Pharmaceuticals industry 144 other companies have achieved higher Quick Ratio than Scilex Holding. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2959 to 4169.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
